Aim: The maximum standardized uptake value (SUVmax) of primary tumors in positron emission tomography can be used to predict prognosis in various cancers, but its significance in recurrent tumors remains unclear. In the present study, we evaluated the utility of the SUVmax for predicting therapeutic effects in recurrent gynecological malignancies. Methods: From February 2012 to July 2014, patients with recurrent gynecological cancer who were treated with chemotherapy or radiotherapy were enrolled in this study. The SUVmax of recurrent lesions before treatment were compared to the therapeutic effects. Results: Fifty patients with recurrent gynecological cancer were enrolled. The mean SUVmax was significantly higher in patients with stable disease/progressive disease than in patients who achieved complete remission/partial remission (13.24 ± 9.78 vs 8.61 ± 5.34, P = 0.039). In patients who were administered chemotherapy, the SUVmax was significantly higher in those with stable disease/progressive disease than in those who achieved complete remission/partial remission (13.24 ± 9.78 vs 8.61 ± 5.34, P = 0.0392) as well as those administered radiotherapy or concurrent chemoradiation therapy (18.15 ± 3.25 vs 11.33 ± 3.98, P = 0.0073). In ovarian cancer patients administered chemotherapy, when the cut-off value of the SUVmax was set as 6.94, the sensitivity and specificity of predicting therapeutic effects were 0.75 and 0.846, respectively. Conclusion: Although the number of enrolled cases was small, our study revealed that the SUVmax in recurrent gynecological tumors might predict therapeutic effects. If the SUVmax is relatively high, multimodal therapy, including surgical removal, should be considered.
Introduction
Gynecological malignancies can result in tumor recurrence, similar to cancers of other sites. In uterine cervical cancer, 10-20% of patients without lymph node metastasis and up to 70% of those with nodal metastases and/or more locally advanced tumors will develop recurrence.
1 Although endometrial cancer generally shows a good prognosis, some patients with stage I disease may develop recurrence. In ovarian cancer, tumor recurrence occurs in approximately 85% of patients with advanced-stage disease, even in those who undergo surgery followed by adjuvant chemotherapy. 2 The prognosis of patients with these recurrent diseases is poor. 3 Generally, the management of patients with recurrence of gynecological malignancies is challenging and complex, and it should include multidisciplinary discussions to determine the optimal therapeutic approach, such as surgery, chemotherapy, or radiotherapy. 4 The treatment strategy for patients with recurrent cancer may be determined based on the performance status of the patients, the metastatic sites, and the number of recurrent lesions. If the recurrent tumor(s) are limited to certain organs, surgical resection could be considered, 4 but if the performance status of the patient is poor, or if they cannot tolerate surgery due to complications, chemotherapy or radiotherapy should be considered rather than surgical treatment. However, objective parameters that could be used to predict the therapeutic effects have not been established; and knowing the potential effect of a therapy before starting treatment would greatly benefit the patient.
In gynecological cancers, recurrence may be diagnosed through routine examination, cytology, serum tumor markers, and imaging methods, such as computed tomography (CT) or magnetic resonance imaging (MRI). In recent years, positron emission tomography (PET) has been reported to be an accurate method for the detection and localization of recurrence in gynecological cancers. [5] [6] [7] [8] It has also been reported to be useful for predicting the prognosis and/or the metastatic activity of primary gynecological tumors through the measurement of the maximum standardized uptake value (SUVmax). [9] [10] [11] Although the SUVmax of primary tumors could predict prognosis, the significance of the SUVmax in recurrent tumors remains uncertain. In this study, the SUVmax in patients with recurrent cervical, endometrial, and ovarian cancer was analyzed retrospectively to determine its prognostic value based on therapeutic outcomes.
Methods
From February 2012 to July 2014, patients diagnosed with recurrence based on PET/CT scans after treatment for gynecological cancers (cervical, endometrial, or ovarian cancer) in our hospital were identified from their medical records. Among them, the patients who received systemic chemotherapy or radiotherapy, including concurrent chemoradiotherapy (CCRT), and who did not undergo surgical removal of their lesions were enrolled in this study. When the recurrence was suspected based on physical examinations, serum tumor markers, and imaging methods, it was eventually confirmed with PET/CT. Therapeutic effect was evaluated with serum tumor markers and imaging methods, such as CT, MRI, or PET/CT after treatment, and it was defined as complete remission (CR), partial remission (PR), stable disease (SD), or progressive disease (PD) according to the Response Evaluation Criteria in Solid Tumors. 12 In every patient, the SUVmax before treatment for recurrent tumors was measured and compared to the therapeutic effect.
A t-test was used for comparison of SUVmax with and without therapeutic effect. A P-value < 0.05 was considered statistically significant.
Results
In total, 50 patients with recurrent gynecological cancer were enrolled in this study. There were 20 cases of cervical cancer, nine cases of endometrial cancer, and 21 cases of ovarian cancer. Some of the patients experienced more than two recurrences. The patients' characteristics are shown in Table 1 . The sites of recurrence are shown in Table 2 . There were 22 cases with lymph node recurrence, 13 cases of pelvic cavity recurrence, 10 cases of peritoneal dissemination, and three cases of recurrence at other sites or organs. In the cases with more than two sites of recurrence, the site that had the greatest SUVmax was evaluated. The treatments for the recurrent tumors are shown in Table 3 . Radiotherapy, chemotherapy, and CCRT were administered to four, 37, and eight patients, respectively. One patient was treated with chemotherapy followed by radiotherapy. The SUVmax according to the therapeutic effect for all cases are shown in Figure 1 . The mean SUVmax for SD/PD cases was significantly higher than that of CR/PR cases (13.24 ± 9.78 vs 8.61 ± 5.34, P = 0.039). The SUVmax according to the primary site and the therapeutic effect are shown in Figure 2 . In patients with ovarian cancer, the SUVmax was significantly higher in those with SD/PD than in those with CR/PR (14.02 ± 11.71 vs 6.45 ± 3.63). In patients with endometrial cancer, the SUVmax was relatively higher in those with SD/PD than in those who achieved CR/PR, but it was not statistically significant. In patients with cervical cancer, there was no significant difference in the SUVmax among patients (13.92 ± 5.49 vs 12.09 ± 5.07, P = 0.227).
In the patients administered chemotherapy, the SUVmax was significantly higher in those with SD/PD than in those who achieved CR/PR (13.24 ± 9.78 vs 8.61 ± 5.34, P = 0.0392; Fig. 3 ). In the patients administered radiotherapy or CCRT, the SUVmax was significantly higher in those with SD/PD than in those who achieved CR/PR (18.15 ± 3.25 vs 11.33 ± 3.98, P = 0.0073, Fig. 4 ). The mean SUVmax for the patients treated with radiotherapy or CCRT in those with CR/PR was higher than that of patients receiving chemotherapy, but the difference was not statistically significant (P = 0.0857, Fig. 5 ). Figure 6 presents the receiver-operator curve (ROC) of the SUVmax for recurrent ovarian cancer patients who were treated with chemotherapy. According to the Cervix  10  7  2  1  Endometrium  2  3  2  2  Ovary  10  3  6  2 The most recurrent site was the lymph nodes followed by the pelvic cavity and the peritoneum. In endometrial cancer, the SUVmax was higher in SD/PD patients than in CR/PR patients, but the difference was not statistically significant (P = 0.0686). (c) In ovarian cancer, the SUVmax was significantly higher in SD/PD patients than in CR/PR patients (*P = 0.0231).
Figure 3
Maximum standardized uptake value (SUVmax) and therapeutic effect in patients administered chemotherapy (n = 37). In stable disease (SD)/progressive disease (PD) patients, the SUVmax was significantly higher than in complete remission (CR)/partial remission (PR) patients (*P = 0.0392).
Figure 4
Maximum standardized uptake value (SUVmax) and therapeutic effect in patients administered radiotherapy or chemoradiotherapy (n = 12). In stable disease (SD)/progressive disease (PD) patients, the SUVmax was significantly higher than in complete remission (CR)/partial remission (PR) patients (*P = 0.0073).
ROC, when the cut-off value of the SUVmax was set as 6.94, the sensitivity and specificity for predicting the chemotherapeutic effect were 0.75 and 0.846, respectively. The overall survival rate of the patients whose SUVmax was below 6.94 was 66.7%, while it was 40% of those above this cut-off level.
Discussion
SUVmax measured using PET could predict prognosis in various cancers, such as liver, kidney, pancreas, and breast cancer. [13] [14] [15] [16] In gynecological cancers, the SUVmax has also been reported to be useful for Figure 5 Maximum standardized uptake value (SUVmax) by type of therapy in patients with complete remission (CR)/ partial remission (PR). In the patients treated with radiotherapy (RT) or concurrent chemoradiotherapy (CCRT) in those with CR/PR, the SUVmax was higher than in those treated with computed tomography (CT), but there was no statistically significant difference (P = 0.0857).
Figure 6
Receiver-operator curve (ROC) of the maximum standardized uptake value (SUVmax) in recurrent ovarian cancer patients administered chemotherapy. When the cut-off value of the SUVmax was set as 6.94, the sensitivity and specificity of predicting the chemotherapeutic effect were 0.75 and 0.846, respectively.
predicting the prognosis or the aggressiveness of cancers.
In squamous cell carcinoma of the uterine cervix, a high pretreatment SUVmax in the context of lymph node metastasis is associated with a poor prognosis. 9 The nodal SUVmax of pretreatment F-18 fludeoxyglucose PET/CT may be a prognostic biomarker for the prediction of recurrence in locally advanced cervical cancer. 17 In endometrial cancer, the SUVmax is also a useful predictive marker, 10 and it is correlated with risk factors for recurrence, such as FIGO stage, deep myometrial invasion, cervical invasion, and lymph node metastasis, 18 as well as overall survival. 11 In ovarian cancer, a positive PET scan was associated with poor overall survival, but semiquantitative data were not proven to be an effective tool to predict disease progression. 19 Yamamoto et al. reported that metabolic tumor volume and total lesion glycolysis could predict the prognosis of ovarian cancer patients who underwent primary surgery followed by platinum-based chemotherapy. 20 As described above, the pretreatment assessment of the SUVmax could be useful for predicting the risk of recurrence. Recently, Onal et al. reported that the pretreatment SUVmax in pelvic lymph nodes was associated with recurrence and a worse prognosis. 21 However, the significance of the SUVmax in recurrent tumors remains unclear. In this study, we sought to evaluate the predictive value of the SUVmax in PET for therapeutic effect in recurrent gynecological malignancies.
The present study revealed that the SUVmax may correlate with the effect of therapies such as radiotherapy or chemotherapy. Particularly in patients with recurrent ovarian cancer, the pretreatment SUVmax could reflect and predict the therapeutic effect. In recurrent cervical cancer, the SUVmax was not significantly different between CR/PR and SD/PD cases. This result may be partially explained by the fact that radiotherapy or CCRT was performed more frequently in recurrent cervical cancer than other cancers, and the SUVmax in the patients treated with radiotherapy/CCRT were higher than those receiving chemotherapy.
The management of recurrent gynecological malignancies is still controversial. When recurrence is encountered, gynecologists should select the appropriate therapeutic procedures, including surgery, chemotherapy, radiotherapy, or some combination of these. Peiretti et al. reported that therapeutic strategies for recurrent cervical cancer should be determined after considering the type of primary therapy, the site of recurrence, the disease-free interval, and the patient's symptoms. 22 This strategy could be adapted to the other gynecological cancers. In some recurrent cases, surgical removal of recurrent tumors might provide a better prognosis. In recurrent cervical cancer, extended pelvic resection is associated with prolonged survival. 23 In ovarian cancer, patients with one or two radiographical recurrence sites, a diagnosis-to-recurrence interval-18 months, and complete secondary cytoreduction were associated with long post-recurrence survival. 24 Currently, a trial is underway to compare cytoreductive surgery followed by chemotherapy versus chemotherapy alone for recurrent platinum-sensitive epithelial ovarian cancer. 25 In recurrent endometrial cancer, cytoreductive surgery is associated with prolonged survival if complete or optimal surgery can be achieved. 26, 27 The role of radiotherapy has been established in recurrent cervical cancer. 22 In recurrent endometrial and ovarian cancer, radiotherapy is one option, but there is no clear consensus regarding the optimal treatment strategy. 28, 29 If objective parameters predicting the effect of chemotherapy or radiotherapy could be established, patients with recurrent disease could avoid receiving ineffective therapies, and they could have better treatment and an improved prognosis.
Our study showed that a high SUVmax in recurrent tumors could be associated with a poor response to chemotherapy or radiotherapy. As such, measurement of the SUVmax in recurrent lesions could be helpful for determining treatment strategies for gynecological cancer patients. When recurrent disease has a relatively high SUVmax, surgical removal of the lesion might be considered and discussed if applicable. As shown in Figure 5 , the SUVmax in patients with CR/PR treated with radiotherapy or CCRT tended to be higher than that of patients treated with chemotherapy. This result suggests that radiotherapy or CCRT might provide a better effect than chemotherapy in recurrent gynecological malignancies. Although the number of cases was small, an SUVmax > 6.94 appeared to be a reasonable cut-off value for predicting the chemotherapeutic effect in the recurrent ovarian cancer patients in our study. Definitive cut-off values could be determined after accumulating a much larger series of recurrent gynecological cancer patients.
In conclusion, to the best of our knowledge, the present study is the first to demonstrate the predictive value of the SUVmax in recurrent gynecological malignancies. If the SUVmax of recurrent lesions is high, the disease might show resistance to chemotherapy or radiotherapy. If indicated, surgical resection or multimodal therapy should be considered in these cases.
